Alpine Immune Sciences, Inc. (ALPN)
NASDAQ: ALPN · IEX Real-Time Price · USD
64.42
+0.05 (0.08%)
At close: Apr 15, 2024, 4:00 PM
64.40
-0.02 (-0.03%)
Pre-market: Apr 16, 2024, 7:51 AM EDT
Alpine Immune Sciences Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for ALPN stock have an average target of 52.29, with a low estimate of 22 and a high estimate of 65. The average target predicts a decrease of -18.83% from the current stock price of 64.42.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ALPN stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 2 |
| Buy | 5 | 4 | 4 | 5 | 6 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 7 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 16, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $42 → $65 | Buy → Hold | Downgrades | $42 → $65 | +0.90% | Apr 12, 2024 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $41 → $65 | Buy → Hold | Downgrades | $41 → $65 | +0.90% | Apr 11, 2024 |
| Wedbush | Wedbush | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Apr 11, 2024 |
| Wolfe Research | Wolfe Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Apr 11, 2024 |
Financial Forecast
Revenue This Year
15.94M
from 58.88M
Decreased by -72.93%
Revenue Next Year
16.65M
from 15.94M
Increased by 4.48%
EPS This Year
-1.73
from -0.64
EPS Next Year
-1.95
from -1.73
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 42.0M | 42.0M | 36.8M | 73.5M | 352.7M |
| Avg | 15.9M | 16.7M | 10.1M | 45.3M | 174.0M |
| Low | n/a | n/a | n/a | n/a | 43.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -28.7% | 163.5% | 120.7% | 625.4% | 678.0% |
| Avg | -72.9% | 4.5% | -39.2% | 347.5% | 283.7% |
| Low | - | - | - | - | -3.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.29 | -1.22 | -1.98 | -1.28 | 1.05 |
| Avg | -1.73 | -1.95 | -2.48 | -2.08 | -0.81 |
| Low | -1.93 | -2.40 | -2.95 | -2.82 | -2.12 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.